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Review
Chikungunya virus: an update on the biology and 
pathogenesis of this emerging pathogen
Felicity J Burt, Weiqiang Chen, Jonathan J Miner, Deborah J Lenschow, Andres Merits, Esther Schnettler, Alain Kohl, Penny A Rudd, Adam Taylor, 
Lara J Herrero, Ali Zaid, Lisa F P Ng, Suresh Mahalingam
Re-emergence of chikungunya virus, a mosquito-transmitted pathogen, is of serious public health concern. In the past 
15 years, after decades of infrequent, sporadic outbreaks, the virus has caused major epidemic outbreaks in Africa, Asia, 
the Indian Ocean, and more recently the Caribbean and the Americas. Chikungunya virus is mainly transmitted by 
Aedes aegypti mosquitoes in tropical and subtropical regions, but the potential exists for further spread because of genetic 
adaptation of the virus to Aedes albopictus, a species that thrives in temperate regions. Chikungunya virus represents a 
substantial health burden to affected populations, with symptoms that include severe joint and muscle pain, rashes, and 
fever, as well as prolonged periods of disability in some patients. The inflammatory response coincides with raised levels 
of immune mediators and infiltration of immune cells into infected joints and surrounding tissues. Animal models have 
provided insights into disease pathology and immune responses. Although host innate and adaptive responses play a 
role in viral clearance and protection, they can also contribute to virus-induced immune pathology. Understanding the 
mechanisms of host immune responses is essential for the development of treatments and vaccines. Inhibitory 
compounds targeting key inflammatory pathways, as well as attenuated virus vaccines, have shown some success in 
animal models, including an attenuated vaccine strain based on an isolate from La Reunion incorporating an internal 
ribosome entry sequence that prevents the virus from infecting mosquitoes and a vaccine based on a virus-like particle 
based expressing envelope proteins. However, immune correlates of protection, as well as the safety of prophylactic and 
therapeutic candidates, are important to consider for their application in chikungunya infections. In this Review, we 
provide an update on chikungunya virus with regard to its epidemiology, molecular virology, virus-host interactions, 
immunological responses, animal models, and potential antiviral therapies and vaccines. 
Introduction
Chikungunya fever is a debilitating arthritic disease 
caused by chikungunya virus. The virus was first 
identified in 1952–53 during an outbreak that occurred in 
the Makonde Plateau in the southern region of Tanzania.1 
The name “chikungunya” is derived from a Swahili or 
Makonde word meaning “that which bends up”, and 
refers to the bending posture of individuals infected with 
the virus.1 The virus belongs to the genus alphavirus of 
the Togaviridae family and, similar to other arthritogenic 
alphaviruses, its infection is commonly characterised by 
acute fever that progresses to severe, persistent arthralgia 
in the chronic stage of disease.2 The disease is usually 
self limiting, but in some patients debilitating joint pain 
can persist for years. The increased frequency of 
outbreaks in the past 15 years appears to be associated 
with a higher incidence of more severe forms of the 
disease than previously described, with reports of cases 
of neurological involvement, fulminant hepatitis, and 
neonatal encephalopathy.3–6 
The virus usually circulates in a sylvatic cycle between 
non-human primates or mammalian reservoir hosts 
and Aedes species mosquitoes. During urban 
epidemics, chikungunya virus can be transmitted to 
human hosts through infectious bites by Aedes spp 
mosquitoes.7 Since 2000, the incidence of large 
outbreaks has increased with spread of the virus to 
previously non-endemic regions; moreover, con-
comitant evidence of genetic adaptation of chikungunya 
virus to Aedes albopictus has implications for the spread 
of the virus to non-endemic regions.8,9 Aedes aegypti is 
found in tropical and subtropical regions, whereas 
A albopictus has a wider distribution and is found in 
temperate regions. Outbreaks of disease caused by an 
East Central South African (ECSA) genotype have been 
reported in Europe.10–12 Although these outbreaks have 
been sporadic without extensive spread, the presence 
of A albopictus raises concerns about the potential for 
the virus to establish endemicity in southern Europe.10,11 
In contrast to the sporadic outbreaks occurring in 
Europe, the virus was identified in the western 
hemisphere in October, 2013, when an outbreak caused 
by the Asian genotype was identified on Saint Martin 
Island. From there, the virus has rapidly spread with 
autochthonous transmission confirmed in multiple 
countries and territories in the Caribbean and the 
Americas.13–16 A albopictus, present in southern and 
eastern regions of the USA, is a potential vector for 
further spread of this virus and establishment of 
endemic regions in the USA. The current outbreaks of 
arboviruses such as chikungunya virus, Zika virus, and 
yellow fever virus highlight the importance of 
understanding the epidemiological factors contributing 
to these epidemics, promoting pathogenicity, and 
affecting control measures. 
Chikungunya virus continues to cause large epidemics 
worldwide, with no specific treatment or vaccine 
currently available to prevent infection. In this Review, 
we provide an update on chikungunya virus with regard 
to its epidemiology, molecular virology, virus-host 
interactions, immunological responses, animal models 
of disease, and potential antiviral therapies and vaccines.
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Genome organisation and molecular structure 
of chikungunya virus
Chikungunya virus has an approximately 12 kb positive-
sense RNA genome that encodes four non-structural 
proteins (nsP1–4), with five structural proteins (C, E3, E2, 
6K, and E1) expressed from subgenomic RNA synthesised 
in infected cells. The genome has a short 5′ untranslated 
region and a longer 3′ untranslated region comprising 
stem-loop structures and direct repeats that are thought 
to be associated with adaptation of the virus to mosquito 
hosts.17 The genome is packed into virions that are similar 
to those of other alphaviruses. The cellular receptors for 
chikungunya virus remain unknown. Chikungunya 
virions are internalised by clathrin-mediated endocytosis, 
but the available evidence also suggests that the entry 
pathway might be cell-type specific or that multiple 
pathways are used.18 
Replication of chikungunya virus RNA is preceded by its 
translation, which results in the production of 
non-structural (ns) polyproteins P123 and P1234. The non-
structural polyproteins are processed into mature non-
structural proteins by the protease activity of the nsP2 
region.19 Mature nsP1 plays a role in viral replication as 
described for other alphaviruses. In addition to 
having enzymatic activities, including NTPase and RNA 
triphosphatase activity,20 RNA helicase activity,21 and 
protease activity,19 nsP2 can counteract host cellular 
antiviral responses through multiple mechanisms. These 
mechanisms include general transcriptional shutdown by 
degradation of the Rpb1 subunit of host cellular RNA 
polymerase II,22 as well as more specific mechanisms 
including interference with JAK/STAT signalling,23,24 the 
unfolded protein response,25 and autophagy.26 The three-
dimensional structure of the N-terminal (macro) domain 
of nsP3 has been resolved and shown to bind negatively 
charged polymers, including RNA.27 Increasing evidence 
also suggests that the intrinsically unstructured C-terminal 
region of nsP3 acts as a binding platform for numerous 
host cellular proteins, including G3BP proteins24,28 and 
amphiphysins,29 and that these interactions are important 
for virus infection. Despite the absence of direct evidence, 
nsP4 of chikungunya virus clearly appears to be an RNA-
dependent-RNA polymerase. 
Considerable attention has been dedicated to the 
identification of host proteins that interact with the non-
structural proteins of chikungunya virus.30–33 Cellular 
proteins also interact with viral RNA.34 In most cases the 
functional importance of these interactions remains 
unknown. However, some interactions have a positive 
effect on virus replication, whereas others mediate 
antiviral effects. Some interacting proteins might have 
both proviral and antiviral effects. For example, the 
interaction of nsP3 of alphaviruses with G3BP proteins 
has an antiviral effect by preventing the formation of 
stress granules.35 A proviral function for G3BP proteins 
has been shown, with depletion of these proteins 
resulting in inhibition of early replication.36 
One possible role of G3BP proteins is to facilitate 
switching from non-structural protein translation to 
replication of genomic RNA;36 however, the exact details 
of RNA replication of chikungunya virus have not been 
studied. By analogy with Semliki Forest virus and Sindbis 
virus, replication first generates negative-strand RNA, 
probably existing exclusively in duplex form with the 
positive-strand genome, and then generates numerous 
positive—genomic and subgenomic—RNAs.37 Genomic 
RNA contains a packaging signal that, unlike most of the 
alphaviruses, is located in the region encoding nsP2.38
Structural proteins, which are essential for virion 
formation, are translated from subgenomic RNA. 
Chikungunya infection shuts down translation of cellular 
mRNAs, and subgenomic RNA remains the only actively 
translated mRNA in the cell.39 Unlike Semliki Forest virus 
and Sindbis virus, subgenomic RNA of chikungunya virus 
does not have a stable stem-loop structure, the so-called 
capsid enhancer, at its 5′ region (Merits A, unpublished). 
Thus, how active translation of chikungunya virus RNA is 
maintained remains unclear. The first structural protein, 
the capsid protein, is not only responsible for nucleocapsid 
formation but also possesses nuclear export and import 
signals allowing entry to and exit from the nucleus.40 The 
glycoprotein part of the structural polyprotein is translated 
by membrane-associated ribosomes and is processed and 
post-translationally modified by cellular enzymes. The 
assembly and budding of chikungunya virions takes place 
on the plasma membrane of infected vertebrate cells. This 
process is sensitive to antiviral effects of the cellular 
protein tetherin,41 which are counteracted by nsP1.42 In 
polarised cells, the release of chikungunya virions occurs 
at the apical domain of cells; data obtained with different 
inhibitors suggest that the N-glycans of chikungunya 
virus envelope glycoproteins could serve as apical sorting 
signals.43
Epidemiology and evolution of chikungunya virus
Chikungunya virus was first isolated in 1952 in Tanzania.1 
Before 2000, outbreaks of chikungunya virus occurred 
sporadically, with reports of naturally acquired human 
infection from Angola,44 Benin,45 Burundi,46 Cameroon,47,48 
the Central African Republic,49 Democratic Republic of 
the Congo,50 Gabon,51 Guinea,52 Kenya,53 Liberia,54 
Madagascar,55 Malawi,56 Nigeria,57 Uganda,58 Senegal,59 
Sierra Leone,60 southern Africa,3,54,60 Sudan,61 and 
Tanzania.1 
The virus is believed to have originated in Africa, with 
subsequent spread to Asian countries probably occurring 
via shipping. The earliest confirmation of disease caused 
by chikungunya virus in Asia was reported from the 
Philippines in 1954. Outbreaks have subsequently been 
reported in southern and southeast Asia, including 
Bangladesh, Bhutan, Cambodia, China, India, Indonesia, 
Laos, Malaysia, Maldives, Burma/Myanmar, Pakistan, 
Saudi Arabia, Singapore, Sri Lanka, Taiwan, Thailand, 
Timor, Vietnam, and Yemen.62–68 Genetic analyses of 
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strains have identified three distinct lineages of 
chikungunya virus: the West African lineage, the ECSA 
lineage, and the Asian lineage9,69,70 derived from the 
ECSA virus. 
Since 2000 the virus has been re-emerging, causing 
several outbreaks of more severe forms of the disease 
than previously reported.50,71 In 2004 an epidemic strain 
of the ECSA lineage emerged and spread from coastal 
towns of Kenya to the Indian Ocean islands, causing an 
outbreak of unprecedented magnitude.72–76 Concurrently, 
re-emergence of the virus was reported in India, after an 
absence of 32 years, affecting 13 different states during 
2005–06.77,78
The epidemic strain of chikungunya virus circulating 
during the outbreak in the Indian Ocean islands, referred 
to as the Indian Ocean Lineage, was likely to have been 
transmitted primarily by A albopictus, the predominant 
mosquito in the region at that time. In later stages of the 
outbreak, the Indian Ocean Lineage appeared to acquire 
a mutation in the envelope glycoprotein (the E1-A226V 
mutation). This mutation contributed to a gain of fitness 
adaptation for dissemination by A albopictus, and the 
ability of the virus to adapt and replicate in this vector 
probably contributed to the magnitude of the outbreak.8 
Interestingly, although the E1-A226V mutation improves 
the ability of the virus to infect and replicate in 
A albopictus, it has no effect on infection of A aegypti.8,79–81
Although the outbreaks in the Indian Ocean islands 
and India have been attributed to an ECSA strain with 
very high nucleotide similarity between isolates from 
India and from the Indian Ocean islands, the mutation 
that is putatively associated with adaptation to A albopictus 
was not detected in isolates circulating in India in 2005. 
Evidence from a mosquito isolate collected in 
Maharashtra in 2000 suggests that a switch in the 
circulating chikungunya virus genotype, from Asian to 
African, occurred in India before the 2004 outbreak in 
the Indian Ocean islands and before the 2005 outbreak 
in India77 (figure 1).
In the western hemisphere chikungunya virus was 
initially identified on Saint Martin Island in October, 2013, 
and from there the virus rapidly spread to countries and 
territories in the Americas.14,15 From the onset of 
the outbreak to early August, 2016, autochthonous trans-
mission of the virus has been confirmed in 48 countries or 
territories in the Caribbean, Central America, 
South America, and North America, with more than 
1 million suspected cases. The spread and establishment 
of the virus in new endemic regions is likely to be 
dependent on the availability of competent vectors. 
Genetic characterisation showed that the strain 
circulating in the Caribbean and Americas is an Asian 
strain, closely resembling the strains circulating in the 
Philippines (2013),82 China (2012), and Yap (2013) in 
southeast Asia14,83 (figure 1). In addition, ECSA strains 
identified in Brazil in 2014 resemble the strains circulating 
in Angola, with evidence of infection occurring in local 
residents with no travel history.84
Vectors and arbovirus-vector interactions
Innate immune responses of the mosquito vector are 
important in controlling the replication and transmission 
of chikungunya virus. Immune pathways in A aegypti 
mosquitoes—such as Toll, JAK-STAT, and Imd—have 
West African lineage
ECSA lineage
ECSA diverged IOL E1-226A
ECSA diverged IOL E1-226V
Asian lineage
Figure 1: Distribution of chikungunya virus
The figure shows the spread and divergence of the East Central South African (ECSA) lineage to the Indian Ocean islands (IOLs) and Asia,9,72,73 the spread of the Asian lineage 
to the Americas in 2013,86 and the spread of the ECSA lineage to Brazil in 2014.87 Autochthonous cases identified in Europe and their genetic lineage are shown.10–12
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antiviral roles.85 Although chikungunya virus infection can 
repress induction of the Toll pathway in vitro, no antiviral 
effect has been observed for the Toll, JAK-STAT, and Imd 
pathways in A aegypti cells.86 RNA interference (RNAi) is 
believed to be the main mosquito antiviral response. RNAi 
can be categorised into several distinct pathways, on the 
basis of the small RNAs involved: 21-nucleotide small 
interfering RNA (siRNA), 21–22-nucleotide microRNA 
(miRNA), and 24–30-nucleotide piwi-interacting RNA 
(piRNA) pathways.87 Each pathway has distinct roles in 
cellular processes and arbovirus-host interactions. The 
antiviral role of the siRNA pathway has been established 
for mosquito-borne arboviruses, and research88 suggests a 
similar activity for the piRNA pathway in Aedes spp 
mosquitoes. Chikungunya-specific siRNAs and piRNAs 
have been reported in infected Aedes spp mosquitoes and 
cell lines, indicating that these RNAs have antiviral 
activity.88 This is supported by the ability of the siRNA 
pathway, specifically the protein Argonaute-2, to limit the 
spread of chikungunya infection,86 and the reported 
increase in virus production and pathogenicity in 
mosquitoes infected with chikungunya virus and 
expressing suppressor proteins that interfere with the 
siRNA pathway.88 In vertebrates and invertebrates, the 
miRNA pathway is important in regulating gene 
expression on a post-transcriptional level;89 however, little 
is known about the interactions of arboviruses with the 
mosquito miRNA pathway. Changes in miRNA expression 
following chikungunya infection have been reported in 
A albopictus cells, with upregulation and downregulation 
observed. Target predictions identified the involvement of 
mosquito mRNAs in many pathways, but more research is 
needed to validate these targets. Combinational analysis of 
differentially expressed miRNAs in mosquito cells infected 
with chikungunya virus versus those infected with 
Plasmodium spp showed that most of these miRNAs are 
regulated in a pathogen-specific manner.90 Similarly, 
differential expression of miRNAs has been reported in 
the saliva of A aegypti and A albopictus mosquitoes infected 
with chikungunya virus. Although none of the targets is 
yet known, inhibition studies in mosquito and mammalian 
cells showed a reduction in chikungunya virus production, 
suggesting an interaction between the virus and the 
miRNA pathway.91 The presence of these miRNAs in 
mosquito saliva and in mammalian cells could point to an 
effect in the vertebrate host.
Clinical presentation
Patients with acute chikungunya virus infection usually 
have an abrupt onset of high fever (>39°C), severe 
arthralgia and myalgia, and an erythematous, maculo-
papular rash, which can range in severity from a mild, 
localised rash to an extensive rash involving more than 
90% of the skin92 (figure 2). The abrupt onset of these 
symptoms occurs after a mean incubation period of 
3 days. The rash and fever usually resolve within a few 
days and are occasionally followed by palmoplantar 
desquamation.59 Less common symptoms include ocular 
manifestations such as conjunctivitis, uveitis, episcleritis, 
and retinitis.93 About 15% of individuals infected with 
chikungunya virus are asymptomatic.92 Most patients 
have joint pain and swelling with severe morning 
stiffness, consistent with inflammatory arthritis92 
(figure 2). The joint pain is typically symmetrical and 
almost any joint can be affected, especially during the 
acute phase, although the distal extremities are affected 
more frequently.92,94,95 Synovitis or periarticular swelling 
has been reported in 32–95% of patients, with large joint 
effusions occurring in 15% of individuals infected with 
chikungunya.96–98 In many patients, chikungunya-related 
joint pain begins to improve after the first week, although 
some patients have persistent joint pain, swelling, and 
morning stiffness. These symptoms can last for up to 
3 years.99,100 
Death from chikungunya infection is rare and occurs 
in fewer than one in 1000 individuals.4 However, 
severe infection can present with encephalitis and 
encephalopathy, myocarditis, hepatitis, and multi-organ 
failure. Neuroinvasion by chikungunya virus, causing 
seizures, altered mental status, flaccid paralysis, and even 
death, occurs infrequently.6,101–103 Case reports point to a 
heightened risk of severe disease in neonates, elderly 
people aged above 65 years with other underlying medical 
conditions, and immunosuppressed individuals. Severe 
neonatal chikungunya infection, including infection 
resulting from mother-to-child transmission, was 
documented in the La Reunion epidemic.104 In neonates 
born to mothers with viraemia, the prevalence [A: is this 
correct?] of infection reached 50%. Neuroinvasion was 
reported in 22 out of 24 neonatal cases. Children with 
chikungunya-associated encephalopathy have poor long-
term neurocognitive outcomes, which can include severe 
sequelae such as microcephaly and cerebral palsy.105 In 
addition to neuroinvasive disease, some neonates develop 
a haemorrhagic syndrome, necrotising enterocolitis, 
haemo dynamic disorders, ventricular dysfunction, 
pericarditis, and coronary artery dilatation.101,104 
Persistent arthralgia occurs after resolution of the acute 
phase of infection (7–10 days). Multiple joints are usually 
affected in the chronic phase, especially the small joints 
of the hands, feet, ankles, and wrists92,94 (figure 2), 
although larger joints could also be affected. Remarkably, 
some patients develop bone erosions as a result 
of chikungunya-induced arthritis.106–108 The exact 
prevalence of bone erosions is yet to be determined, but 
bone erosions might be a less common phenomenon. 
Nonetheless, the ability of chikungunya to cause erosive 
disease distinguishes arthritogenic alphaviruses from 
other forms of viral or post-viral arthritis.
Persistent joint pain caused by chikungunya virus 
infection is often debilitating, and the natural course of 
disease involves gradual improvement until complete 
resolution of symptoms. In La Reunion, up to 60% of 
patients had relapsing and remitting arthralgia up to 
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36 months after being diagnosed with acute disease.100 
Risk factors for the development of long-term arthralgia 
following chikungunya virus infection include age 
(>35 years) and the presence of arthralgia in the first 
4 months after onset of symptoms.100 A further 
complicating diagnostic issue is that persistent 
chikungunya-induced joint pain can mimic symptoms 
of rheumatoid arthritis. Similarities between the 
persistent phase of chikungunya and rheumatoid 
arthritis could confound the diagnosis, although most 
patients infected with chikungunya virus have an abrupt 
onset of arthritis and fever, which would be unusual in 
adult-onset rheumatoid arthritis. However, acute joint 
pain caused by chikungunya is not always diagnostically 
distinguishable from juvenile idiopathic arthritis or 
systemic-onset juvenile rheumatoid arthritis, which are 
frequently associated with fever and rash. Although 
chikungunya-induced joint pain is self limiting, the 
prolonged and severe nature of the illness can have a 
major impact on society in terms of morbidity and 
economic productivity.99 
Pathogenesis of chikungunya virus
During the early and acute phase of infection, high titres 
of chikungunya virus are present in the blood, resulting 
in viraemia that can be detected by real time PCR within 
the first few days of infection. The resulting inflammatory 
response coincides with elevation of immune mediators 
followed by infiltration of immune cells into infected 
joints and surrounding tissues.
Patients with acute and chronic chikungunya virus 
infection have high concentrations of circulating cytokines 
and chemokines.109–111 However, considerable variation 
exists among results from these studies. A meta-analysis112 
found raised levels of numerous serum and plasma 
cytokines in cohorts of patients from different regions of 
the world. Chikungunya virus infection resulted in raised 
concentrations of several pro-inflammatory cytokines 
(interferon-α, interferon-γ, interleukin-6, and others), 
anti-inflammatory cytokines (interleukin-1 receptor-a, 
interleukin-4, and interleukin-10), and other chemokines 
such as IP-10 and monocyte chemotactic protein 1.112 
The number of circulating activated and effector T cells 
is increased in patients with persistent chikungunya-
induced arthritis,92 and studies in mice suggest that 
T cells play a major role in the pathogenesis of 
chikungunya-induced arthritis.113 Patients infected with 
chikungunya develop a robust antibody response, with 
IgM concentrations detectable within days of infection 
and neutralising anti-chikungunya IgG typically 
measurable in the second week of infection. Antibodies 
to chikungunya are important for clearance of the 
infectious virus.114 Neutralising anti-chikungunya IgG 
persists for at least 21 months115 and probably for years, 
thereby providing strong antiviral immunity that 
prevents clinical symptoms in the event of a second 
infection with chikungunya virus. Potently neutralising 
human monoclonal antibodies to chikungunya are 
known to bind the E2 envelope glycoprotein.116 
In addition to T and B cells, which are involved in 
pathogenesis of chikungunya virus, multiple other cell 
types are likely to play a role during infection. Animal 
models and in vitro studies have shown that chikungunya 
virus infects multiple cell types, including dendritic cells, 
macrophages, synovial fibroblasts, endothelial cells, and 
myocytes.2 Chikungunya virus infects human osteoblasts 
and causes cytopathic effects,117 which could contribute to 
the joint pathology and erosive disease. Moreover, greater 
numbers of natural killer cells have been found in the 
peripheral blood of patients with persistent chikungunya-
induced arthritis than in healthy controls.92
Most studies have focused on the innate immune 
response during acute chikungunya virus infection. Why 
a subset of patients develop persistent arthritis is unclear, 
BA
Figure 2: Clinical features of disease in patients with chikungunya virus infection
(A) Maculopapular rash during the acute infectious phase. The rash was distributed over the entire body, resolved after a few days, and was followed by 
desquamation. The patient was a white woman aged 33 years. The patient developed fever, diffuse arthritis, and an erythematous, maculopapular rash over her entire 
body. (B) Active symmetric synovitis in the metacarpophalangeal and proximal interphalangeal joints during the chronic phase of chikungunya-associated arthritis. 
The patient was a white man aged 57 years. The patient developed high fever, a diffuse maculopapular rash, joint pain, stiffness, and swelling consistent with an acute 
pattern. Both individuals travelled to Haiti during a chikungunya virus outbreak. Figure reproduced from Miner JJ et al, Arthritis Rheumatol 2015; 67: 1214–20,95 by 
permission of John Wiley & Sons, Inc. [A: panels A and B swapped to match revised text — OK?]
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and the immune pathways that control or trigger these 
chronic symptoms remain undefined. At least 
three hypotheses have been put forward to explain why 
patients with chikungunya frequently develop chronic 
arthritis: 1) persistence of the infectious virus; 2) 
persistence of viral nucleic acids, which could trigger 
persistent immunopathology; and 3) triggering of 
persistent immune activation in certain individuals after 
the infectious virus has been cleared. Although none of 
these hypotheses has been proven correct, clinical studies 
and animal models have yielded intriguing results. For 
example, viral proteins have been detected in macro-
phages in chikungunya-infected macaques long after 
acute infection has resolved, suggesting persistence of 
the infectious virus.118 However, infectious virus has 
never been cultured from patients after the first week of 
infection, suggesting that replicating but defective viral 
genomes—which are unable to produce infectious 
virus—might persist in the joints of infected individuals. 
Additional studies are required to distinguish between 
these intriguing possibilities and to develop effective 
therapeutics, especially because immunosuppressive 
medications could be deleterious in the context of a 
persistent infection.
Insights from non-human primate and 
mouse models
The first studies of chikungunya virus infection in non-
human primates were done in the late 1960s in rhesus 
macaques (Macaca mulatta) and bonnet macaques 
(Macaca radiata).119,120 These studies showed the 
susceptibility of non-human primates to chikungunya 
virus infection and the transmissibility of chikungunya 
virus from mosquitoes to non-human primates. In 2010, 
Labadie and colleagues118 developed a more detailed 
primate model by intravenously infecting cynomolgus 
macaques (Macaca fascicularis) with a chikungunya virus 
isolate (LR2006-OPY1) from the La Reunion outbreak. 
Infected macaques developed clinical signs of 
chikungunya that closely resembled those seen in 
individuals with chikungunya.118 During acute infection, 
high amounts of chikungunya virus RNA were detected 
in the spleens, lymph nodes, and livers, and comparatively 
lower amounts detected in joints, muscle, skin, and the 
CNS. Analysis of the subacute and chronic phases 
showed that secondary lymphoid organs were infiltrated 
by macrophages, and chikungunya virus antigens were 
present in several tissues, including lymphoid organs, 
meninges, joints, and muscles.118 
To examine the potential for vertical transmission of 
chikungunya virus infection, pregnant non-human 
primates were inoculated subcutaneously with 
chikungunya virus from either the ECSA or the Asian 
lineages.121 Vertical transmission of chikungunya virus 
was not seen, suggesting that in cases where neonates 
are born to mothers with viraemia, transmission of 
chikungunya from mother to child is likely to occur 
during delivery rather than vertically in utero.121 
Age-related immunity has also been investigated in 
non-human primates, with old animals (aged over 
17 years) compared with adult animals (aged 6–13 years).122 
Findings suggest that immune senescence can affect 
both innate and adaptive immune responses to 
chikungunya.
The most widely documented mouse models of acute 
chikungunya infection involve subcutaneous ventral 
footpad injection of the virus in either young wild-type 
C57BL/6 mice (3–4 weeks of age) or adult wild-type 
C57BL/6 mice (>6 weeks of age).113,114,123,124 A study124 found 
a severe reduction in bone volume in the tibial epiphysis 
of the knee in chikungunya-infected mice. Disruption of 
the receptor activator of nuclear factor-κB ligand (RANKL) 
and osteoprotegerin ratio in infected bone tissue 
promoted a pro-osteoclastic microenvironment and bone 
resorption. Moreover, dampening recruitment of 
monocytes and macrophages to skeletal joints of 
chikungunya-infected mice with the use of bindarit, a 
monocyte chemotactic protein inhibitor, reduced 
osteoclastogenesis and prevented severe bone loss. 
Interestingly, studies have identified a dual role for 
CCR2+ monocytes and macrophages not only as inducers 
of footpad swelling and inflammatory pathologies but 
also in preventing excessive inflammatory pathology and 
resolving chikungunya-induced inflammation.124,125 With 
this in mind, the absence of CCR2 in chikungunya-
infected mice resulted in increased neutrophil infiltration 
in joints, leading to erosive cartilage damage. Overall, 
findings from mouse models of acute chikungunya 
infection have provided new insights into chikungunya 
disease pathophysiology. 
Early mouse models of chikungunya virus used 
immunologically immature neonates or mice with 
abrogated type I interferon responses. Since then, the role 
of the innate immune response in the pathogenesis of 
chikungunya virus has been examined extensively.124,126,127 
Musculoskeletal inflammatory disease following 
chikungunya infection is greatly exacerbated in the 
absence of responses dependent on STAT1 signalling and 
type I interferon receptor signalling.127 Moreover, RIG-I/
MDA-5 signalling via IPS-1, the TLR3/TRIF pathway, 
and, to a lesser extent, MyD88-dependent signalling are 
important for interferon-α and interferon-β production in 
response to chikungunya infection.127,128 The contribution 
of CD4+ T cell responses to chikungunya-induced arthritis 
has also been explored, with MHCII and CD4+ knockout 
mice showing considerable reductions in footpad 
swelling following infection.113,129 Viraemia was controlled 
in CD4+ knockout mice, showing the importance of CD4+ 
T-helper-independent antibody responses in minimising 
virus replication.113 Chronic chikungunya infection of 
Rag2–/– mice was replicated in separate studies,114,130 in 
which persistence of chikungunya virus RNA in joint-
associated tissues was associated with histopathological 
evidence of arthritis, synovitis, and tendonitis.130 Anti-
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chikungunya monoclonal antibody therapy had only 
tissue-specific efficacy in clearing chikungunya virus 
from Rag2–/– mice and was not effective in preventing 
persistence of chikungunya infection in the joints.130 
Together, these findings suggest that adaptive immunity 
controls the persistence of chikungunya infection, which 
subsequently leads to the chronic musculoskeletal tissue 
pathology. 
Control strategies: antivirals, vaccines, and 
antibodies
No licensed vaccine or antiviral drug is available against 
chikungunya virus. Current treatment mainly involves 
the use of anti-inflammatory drugs for symptomatic 
relief. During the La Reunion outbreaks, chloroquine 
(commonly used as an antimalarial drug) was used for 
clinical treatment of the disease. Although chloroquine 
has strong anti-chikungunya effects in cell culture, it had 
no effects on patients.131 Broad-spectrum antivirals like 
ribavirin and interferon were effective against 
chikungunya,132 whereas mycophenolic acid was shown 
to be more potent than ribavirin in controlling 
chikungunya virus replication in various cellular 
studies.39,133 Further investigation of these drugs will be 
necessary before they can be used for routine clinical 
treatment of chikungunya infection. 
Most drug discovery studies have relied on cell-based 
screens with antiviral compounds that mainly target the 
proteins involved in virus replication.134 The polymerase 
inhibitor favipiravir has been shown to inhibit 
chikungunya virus in cell culture and in a lethal mouse 
model.135 Although the mode of action remains 
undefined, modified nucleosides such as 6-azauridine 
and 3-deaza-adenosine are also active against 
chikungunya virus replication.39 Chikungunya virus 
nsP2 is both a helicase and a protease, and attempts have 
been made to identify known protease inhibitors that 
could inhibit the virus.136
Viral replicase inhibitors such as betulins, trigocherrins, 
and trigocherriolides, as well as 12-O-tetradecanoylphorbol 
13-acetate, a potent tumour inhibitor, are effective against 
chikungunya virus through mechanisms not yet 
determined.137–139 Compounds that interfere with 
chikungunya virus replication by targeting host processes 
have also been reported. These include inhibition of the 
heat shock protein HSP90 and inhibition of kinases and 
other cellular signalling pathways.33,140 The current 
challenge for antiviral compounds against chikungunya 
virus is that, although a number of hits have been 
identified, further research is needed to determine which 
compound will make it to the clinic. 
The first chikungunya vaccines were developed in the 
1960s with formalin-inactivated virus preparations and 
attenuated strains, but none was successful.141,142 Sub-
sequently, an attenuated vaccine candidate, TSI-GSD-218 
(also known as 181/clone25), was developed by the US 
Army Medical Research Institute on the basis of a 
clinical isolate originating from Thailand in 1962.143,144 
However, development of this vaccine was discontinued 
because of a scarcity of funds and insufficient market 
interest.144 Another attenuated vaccine was developed 
with the La Reunion isolate to contain an internal 
ribosomal entry site element between the non-structural 
and the structural genes. This vaccine produced high 
amounts of neutralising antibodies in mice and 
protected the animals from chikungunya virus.145,146 
Cross-protective immunity was also observed against 
o’nyong-nyong virus.147 In non-human primate models, 
this vaccine prevented viraemia following challenge 
with chikungunya virus.148 Other attenuated 
chikungunya vaccines with large deletions in either the 
nsP3 or 6K genes were shown to generate robust 
immune responses after a single immunisation and to 
fully protect mice from a high-dose challenge with 
chikungunya virus.149 
Virus-like particles have also been investigated as 
candidate vaccines.150–152 Virus-like particles encoding 
the capsid and envelope glycoproteins were immuno-
genic in mice and non-human primates, inducing high 
con centrations of protective neutralising antibodies.150,153 
Similarly, a measles-virus-based vaccine, which also 
expressed chikungunya virus-like particles, protected 
susceptible mice from lethal chikungunya virus 
challenge.154 Both of these virus-like particle vaccines 
have been used in clinical trials155,156 in which vaccinated 
healthy adults produced neutralising antibodies to 
chikungunya virus with no reports of adverse events.
Various other strategies have been developed over the 
years, including with non-alphavirus vectors for expression 
of the structural genes of chikungunya virus, which 
completely protected mice from viraemia and arthritis 
after challenge with the La Reunion and Asian isolates.157 
Other candidates successfully tested in mice include the 
vaccine based on a chimeric vesicular stomatitis virus in 
which the glycoprotein (G) gene of vesicular stomatitis 
virus was replaced by the entire region encoding the 
chikungunya virus structural polyprotein,158 and a 
recombinant poxvirus-chikungunya vaccine candidate 
based on the modified vaccinia virus Ankara strain 
expressing the structural genes of chikungunya virus.159 
DNA-based vaccines expressing chikungunya virus 
envelope proteins E3, E2, and E1,160 and the capsid 
protein,161 have been investigated. Use of the 
Search strategy and selection criteria
We searched the electronic database PubMed using the terms 
“chikungunya” or “alphavirus” for manuscripts published 
from Jan 1, 2000 to Aug 31, 2016. We included selected 
publications that provided recent information on 
chikungunya virus with regard to its epidemiology, molecular 
virology, virus-host interactions, immunological responses, 
animal models, and potential antiviral therapies and vaccines. 
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chikungunya virus nsP2 gene as an adjuvant led to 
improved immune responses and better protection of 
the animals following challenge.162 Subunit vaccines 
have also been investigated with bacterially produced 
recombinant E2 and E1 protein antigens delivered in 
combination with a number of different adjuvants. 
These vaccines induced the production of high amounts 
of neutralising antibodies.163,164 
Passive immunisation in various animal models has 
also been shown, including with human polyvalent 
antibodies165 purified polyclonal antibodies from non-
human primates immunised with chikungunya virus-
like particle vaccines,150 and human neutralising 
monoclonal antibodies directed against E2 and 
E1 glycoproteins.166–168 In all of these cases, the antibodies 
exhibited strong neutralising activities and protected 
susceptible adult Ifnar–/– mice and neonatal C57BL/6 
mice from infection. Passive immunisation could 
therefore constitute an effective medical intervention for 
individuals who have been exposed to chikungunya virus 
and are at risk of developing severe disease. 
Nonetheless, as most vaccine candidates and biologics 
have so far been tested only in mice, many remain in the 
preclinical phase; concerted efforts will be required to 
advance these compounds into clinical trials. The 
immune correlates of protection, plus the safety and 
stability of these prophylactic and therapeutic candidates, 
are important aspects to consider in the quest to control 
and treat chikungunya infections.
Conclusion
Novel insights into the mechanisms of the disease 
pertaining to joint and bone damage, as well as the 
dynamics of the protective immune responses, are 
contributing to the development of therapeutics against 
chikungunya. Inhibitory compounds targeting key 
inflammatory pathways, as well as attenuated virus 
vaccines, have shown promising results in animal 
models. However, further characterisation is needed of 
key pathways in host-pathogen interactions and the 
inflammatory cascades that result in disease to help 
design better, more targeted therapies. 
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